{"id":1810,"date":"2021-08-09T21:37:21","date_gmt":"2021-08-09T18:37:21","guid":{"rendered":"http:\/\/larifan.lv\/eraf\/"},"modified":"2025-04-23T14:20:36","modified_gmt":"2025-04-23T11:20:36","slug":"eraf","status":"publish","type":"page","link":"https:\/\/larifan.eu\/en\/eraf\/","title":{"rendered":"ERAF"},"content":{"rendered":"<p>[vc_row overflow=&#8221;default&#8221; css=&#8221;.vc_custom_1643308766592{border-top-width: 60px !important;padding-bottom: 60px !important;}&#8221;][vc_column][vc_single_image image=&#8221;3767&#8243; img_size=&#8221;full&#8221; alignment=&#8221;center&#8221;][vc_column_text]2024.gada 22.apr\u012bl\u012b biedr\u012bba \u201cLatvijas \u0136\u012bmijas un farm\u0101cijas uz\u0146\u0113m\u0113ju asoci\u0101cija\u201d (turpm\u0101k &#8211; biedr\u012bba) un Centr\u0101l\u0101 finan\u0161u un l\u012bgumu a\u0123ent\u016bra parakst\u012bja L\u012bgumu par Eiropas Savien\u012bbas Atvese\u013co\u0161anas fonda projekta \u201cLatvijas Dz\u012bv\u012bbas zin\u0101t\u0146u nozares att\u012bst\u012bbas sadarb\u012bbas t\u012bkla p\u0113tniec\u012bbas un internacionaliz\u0101cijas veicin\u0101\u0161ana\u201d ievie\u0161anu, Projekta nr. Nr. 5.1.1.2.i.0\/3\/24\/A\/CFLA\/003 (turpm\u0101k \u2013 Projekts).<\/p>\n<p>Projekta \u012bsteno\u0161ana notiek sadarb\u012bbas t\u012bkla veid\u0101. Sadarb\u012bbas t\u012bklu veido vair\u0101k k\u0101 30 uz\u0146\u0113mumi, taj\u0101 skait\u0101 SIA Larif\u0101ns,vismaz viena p\u0113tniecisk\u0101 organiz\u0101cija un biedr\u012bba.<\/p>\n<p>Projekts tiek \u012bstenots sekojo\u0161\u0101s RIS3 jom\u0101s:<\/p>\n<p>&#8211; Biomedic\u012bna, medic\u012bnas tehnolo\u0123ijas, biofarm\u0101cija un biotehnolo\u0123ijas;<\/p>\n<p>&#8211; Viedie materi\u0101li, tehnolo\u0123ijas un in\u017eeniersist\u0113mas;<\/p>\n<p>&#8211; Inform\u0101cijas un komunik\u0101ciju tehnolo\u0123ijas.<\/p>\n<p>Projekta ietvaros pl\u0101not\u0101s aktivit\u0101tes ir v\u0113rstas uz jomas presti\u017ea cel\u0161anu un atbilsto\u0161as motiv\u0101cijas sist\u0113mas izveidi, sadarb\u012bbas t\u012bkla izveidi un darb\u012bbu, starptautisk\u0101s sadarb\u012bbas un eksporta apjoma pieauguma veicin\u0101\u0161anu.<\/p>\n<p>Projekts tie\u0161i veicin\u0101s sadarb\u012bbas t\u012bkla dal\u012bbnieku pieeju starptautiskajiem tirgiem, stiprin\u0101s nozares starptautisko konkur\u0113tsp\u0113ju, ka ar\u012b veicin\u0101s nozares popularit\u0101ti jaunatnes vid\u016b.<\/p>\n<p>Projekta aktivit\u0101tes ir v\u0113rstas uz sadarb\u012bbas t\u012bkla dal\u012bbnieku internacionaliz\u0101ciju un priv\u0101to p\u0113tniec\u012bbas un att\u012bst\u012bbas invest\u012bciju apjoma palielin\u0101\u0161anu.<\/p>\n<p>Projekta ilgums: 16.01.2024. \u2013 30.06.2026.<\/p>\n<p>Projekta kop\u0113jais bud\u017eets: 514\u00a0552 EUR<\/p>\n<p>ES Atvese\u013co\u0161an\u0101s fonda l\u012bdzfinans\u0113jums 85%: 437\u00a0369EUR;<\/p>\n<p>Priv\u0101tais l\u012bdzfinans\u0113jums: 77\u00a0183EUR.<\/p>\n<p><span style=\"color: #333333; font-size: 18px;\"><strong>SIA \u201eLARIF\u0100NS\u201d <\/strong>06.05.2016. nosl\u0113dza ar LIAA l\u012bgumu <strong>Nr.SKV-L-2016\/227<\/strong> par atbalsta sa\u0146em\u0161anu projekta &#8220;Starptautisk\u0101s konkur\u0113tsp\u0113jas veicin\u0101\u0161ana&#8221; (projekta idintifik\u0101cijas numurs 3.2.1.2\/16\/I\/001), ietvaros, ko l\u012bdzfinans\u0113 Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonds. <\/span><\/p>\n<p><span style=\"font-size: 18px; color: #000000;\"><strong>SIA \u201eLARIF\u0100NS\u201d<\/strong> 30.11.20215. nosl\u0113dza ar LIAA l\u012bgumu <strong>Nr.L.\u0100TA\/2.3.1.1.1\/15\/79\/137<\/strong> par atbalsta sa\u0146em\u0161anu projekta \u201eViz\u012bte kontaktbir\u017e\u0101 &#8220;BROKERAGE Event Horizon 2020&#8221; Ostrov\u0101, \u010cehij\u0101 2015. gada j\u016bnij\u0101 un izst\u0101d\u0113 CPhI Worldwide Madrid\u0113, Sp\u0101nij\u0101 2015. gada oktobr\u012b\u201d ietavros, ko l\u012bdzfinans\u0113 Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonds.<\/span><\/p>\n<p><span style=\"color: #333333; font-size: 18px;\"><strong>SIA \u201eLARIF\u0100NS\u201d<\/strong> 29.05.2015. nosl\u0113dza ar LIAA l\u012bgumu <strong>Nr.L-\u0100TA-15-2883<\/strong> par atbalsta sa\u0146em\u0161anu projekta <strong>\u201eViz\u012bte Tbilisi, Gruzij\u0101\u201d<\/strong> ietvaros, ko l\u012bdzfinans\u0113 Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonds.<\/span><\/p>\n<p><span style=\"color: #333333; font-size: 18px;\"><strong>SIA \u201eLARIF\u0100NS\u201d<\/strong> 02.04.2015. nosl\u0113dza ar LIAA l\u012bgumu <strong>Nr.L-\u0100TA-15-2703<\/strong> par atbalsta sa\u0146em\u0161anu projekta <strong>\u201eViz\u012bte Tbilisi un Batumi, Gruzij\u0101\u201d<\/strong> ietvaros, ko l\u012bdzfinans\u0113 Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonds.<\/span><\/p>\n<p><span style=\"color: #333333; font-size: 18px;\"><strong>SIA \u201eLARIF\u0100NS\u201d<\/strong> 26.09.2014. nosl\u0113dza ar LIAA l\u012bgumu <strong>Nr.L-\u0100TA-14-2370<\/strong> par atbalsta sa\u0146em\u0161anu projekta <strong>\u201eViz\u012bte Tad\u017eikist\u0101n\u0101 un Mongolij\u0101\u201d<\/strong> ietvaros, ko l\u012bdzfinans\u0113 Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonds.<\/span><\/p>\n<p><span style=\"color: #333333; font-size: 18px;\"><strong>SIA \u201eLARIF\u0100NS\u201d<\/strong> 09.07.2014. nosl\u0113dza ar LIAA l\u012bgumu <strong>Nr.L-\u0100TA-14-2236<\/strong>\u00a0 par atbalsta sa\u0146em\u0161anu projekta <strong>\u201eViz\u012bte Uzbekist\u0101n\u0101\u201d<\/strong> ietvaros, ko l\u012bdzfinans\u0113 Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonds.<\/span><\/p>\n<p><span style=\"color: #333333; font-size: 18px;\"><strong>SIA \u201eLARIF\u0100NS\u201d<\/strong> 18.07.2013. nosl\u0113dza ar LIAA l\u012bgumu <strong>Nr.L-\u0100TA-13-1578 <\/strong>par atbalsta sa\u0146em\u0161anu projekta\u00a0<strong>\u201eViz\u012bte Turkmenist\u0101n\u0101\u201d<\/strong> ietvaros, ko l\u012bdzfinans\u0113 Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonds.<\/span><\/p>\n<p><span style=\"color: #333333; font-size: 18px;\"><strong>SIA \u201eLARIF\u0100NS\u201d<\/strong> 09.07.2013. nosl\u0113dza ar LIAA l\u012bgumu <strong>Nr.L-\u0100TA-13-1556<\/strong> par atbalsta sa\u0146em\u0161anu projekta <strong>\u201eTirdzniec\u012bbas misija Moldov\u0101\u201d<\/strong> ietvaros, ko l\u012bdzfinans\u0113 Eiropas Re\u0123ion\u0101l\u0101s att\u012bst\u012bbas fonds.<\/span><\/p>\n<div class=\"naiskr\">\n<p><span style=\"color: #333333; font-size: 18px;\">2010. gada 1. oktobr\u012b BMC tika uzs\u0101kta ERAF 2.1.1.1. aktivit\u0101tes projekta<strong>\u00a0\u201ePrognostiska im\u016bnterapijas lietder\u012bguma un efektivit\u0101tes test\u0113\u0161ana: metodes izveide personaliz\u0113tai im\u016bnterapeitisko prepar\u0101tu pielieto\u0161anai onkolo\u0123ij\u0101\u201d\u00a0<\/strong>\u012bsteno\u0161ana.<\/span><\/p>\n<p><span style=\"color: #333333; font-size: 18px;\">Projekts tiek \u012bstenots ERAF 2.1.1.1. aktivit\u0101tes \u201eAtbalsts zin\u0101tnei un p\u0113tniec\u012bbai\u201d ietvaros<\/span><br \/>\n<span style=\"color: #333333; font-size: 18px;\">Projekta vieno\u0161an\u0101s Nr. 2010\/0233\/2DP\/2.1.1.1.0\/10\/APIA\/VIAA\/076<\/span><br \/>\n<span style=\"color: #333333; font-size: 18px;\">Projekta izpildes termi\u0146\u0161: 36 m\u0113ne\u0161i (01.10.2010.-30.09.2013.)<\/span><br \/>\n<span style=\"color: #333333; font-size: 18px;\">Projekta kop\u0113jais finans\u0113jums: 294938 LVL<\/span><br \/>\n<span style=\"color: #333333; font-size: 18px;\">Projekta zin\u0101tnisk\u0101 vad\u012bt\u0101ja: Dr. Dace Pjanova<\/span><\/p>\n<p><span style=\"color: #333333; font-size: 18px;\">Projekta\u00a0<strong>visp\u0101r\u012bgais m\u0113r\u0137is<\/strong>\u00a0ir uzlabota onkolo\u0123isko pacientu im\u016bnterapijas efektivit\u0101te.<\/span><\/p>\n<\/div>\n<div><span style=\"color: #333333; font-size: 18px;\">Projekta\u00a0<strong>specifiskais m\u0113r\u0137is<\/strong>\u00a0ir personaliz\u0113tas prognostiskas\u00a0<em>in vitro<\/em>\u00a0test\u0113\u0161anas metodes izveide im\u016bnterapetisko prepar\u0101tu lieto\u0161anas lietder\u012bguma paredz\u0113\u0161anai pirms terapijas uzs\u0101k\u0161anas.<\/span><\/div>\n<div><\/div>\n<div><span style=\"color: #333333; font-size: 18px;\">Lai nodro\u0161in\u0101tu m\u0113r\u0137u sasnieg\u0161anu, projekta ietvaros pl\u0101nots \u012bstenot \u0161\u0101das\u00a0<strong>aktivit\u0101tes<\/strong>:<\/span><\/div>\n<div><\/div>\n<div><span style=\"color: #333333; font-size: 18px;\">1. P\u0113tniec\u012bba (r\u016bpnieciskais p\u0113t\u012bjums):<\/span><\/div>\n<div><span style=\"color: #333333; font-size: 18px;\">1.1. prepar\u0101tu ierosin\u0101to limfoc\u012btu sub-popul\u0101ciju noteik\u0161ana,<\/span><\/div>\n<div><\/div>\n<div><span style=\"color: #333333; font-size: 18px;\">1.2. prepar\u0101tu ierosin\u0101to limfoc\u012btu aktivit\u0101tes noteik\u0161ana,<\/span><\/div>\n<div><\/div>\n<div><span style=\"color: #333333; font-size: 18px;\">1.3. prepar\u0101tu ierosin\u0101to limfoc\u012btu ekspansijas noteik\u0161ana atsevi\u0161\u0137\u0101s sub-popul\u0101cij\u0101s un to<\/span><\/div>\n<div><span style=\"color: #333333; font-size: 18px;\">aktivit\u0101tes noteik\u0161ana da\u017e\u0101d\u0101s onkolo\u0123isko pacientu grup\u0101s,<\/span><\/div>\n<div><\/div>\n<div><span style=\"color: #333333; font-size: 18px;\">1.4. Personaliz\u0113tas prognostiskas im\u016bnterapeitisko prepar\u0101tu efekta in vitro test\u0113\u0161anas<\/span><\/div>\n<div><span style=\"color: #333333; font-size: 18px;\">metodikas izstr\u0101de.<\/span><\/div>\n<div><\/div>\n<div class=\"naiskr\">\n<p><span style=\"color: #333333; font-size: 18px;\">2. P\u0113tniec\u012bbas rezult\u0101tu publiskas pieejam\u012bbas nodro\u0161in\u0101\u0161ana<\/span><\/p>\n<p><span style=\"color: #333333; font-size: 18px;\"><strong>Projekta rezult\u0101t\u0101<\/strong>\u00a0tiks izstr\u0101d\u0101ta personaliz\u0113ta prognostiska im\u016bnterapeitisko prepar\u0101tu lieto\u0161anas lietder\u012bguma un efektivit\u0101tes in vitro test\u0113\u0161anas metodika ar pielietojumu kl\u012bnik\u0101 onkolo\u0123isko pacientu im\u016bnterapijas prognoz\u0113jam\u012bbas paaugstin\u0101\u0161anai un im\u016bnterapijas efektivit\u0101tes palielin\u0101\u0161anai, piemekl\u0113jot katram pacientam piem\u0113rot\u0101ko prepar\u0101tu un devu. Projekta rezult\u0101t\u0101 tiks izstr\u0101d\u0101ts metodes detaliz\u0113ts aprakts.<\/span><\/p>\n<hr \/>\n<\/div>\n<p><span style=\"color: #0000ff; font-size: 18px;\"><a style=\"color: #0000ff;\" href=\"http:\/\/bmc.biomed.lu.lv\/lv\/petijumi\/projekti\/visi-projekti\/prognostiska-imunterapijas-lietderiguma-un-efektivitates-testesana-metodes-izveide-personalizetai-imunterapeitisko-preparatu-pielietosanai-onkologija\/\">Vair\u0101k inform\u0101cijas var apskat\u012bt \u0161eit..<\/a><\/span>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[vc_row overflow=&#8221;default&#8221; css=&#8221;.vc_custom_1643308766592{border-top-width: 60px !important;padding-bottom: 60px !important;}&#8221;][vc_column][vc_single_image image=&#8221;3767&#8243; img_size=&#8221;full&#8221; alignment=&#8221;center&#8221;][vc_column_text]2024.gada 22.apr\u012bl\u012b biedr\u012bba \u201cLatvijas \u0136\u012bmijas un farm\u0101cijas uz\u0146\u0113m\u0113ju asoci\u0101cija\u201d (turpm\u0101k &#8211; biedr\u012bba) un Centr\u0101l\u0101 finan\u0161u un l\u012bgumu a\u0123ent\u016bra parakst\u012bja L\u012bgumu par Eiropas Savien\u012bbas Atvese\u013co\u0161anas fonda projekta \u201cLatvijas Dz\u012bv\u012bbas zin\u0101t\u0146u nozares att\u012bst\u012bbas sadarb\u012bbas t\u012bkla p\u0113tniec\u012bbas un internacionaliz\u0101cijas&#8230;<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"disable_featured_image":false},"aioseo_notices":[],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/larifan.eu\/en\/wp-json\/wp\/v2\/pages\/1810"}],"collection":[{"href":"https:\/\/larifan.eu\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/larifan.eu\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/larifan.eu\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/larifan.eu\/en\/wp-json\/wp\/v2\/comments?post=1810"}],"version-history":[{"count":17,"href":"https:\/\/larifan.eu\/en\/wp-json\/wp\/v2\/pages\/1810\/revisions"}],"predecessor-version":[{"id":3867,"href":"https:\/\/larifan.eu\/en\/wp-json\/wp\/v2\/pages\/1810\/revisions\/3867"}],"wp:attachment":[{"href":"https:\/\/larifan.eu\/en\/wp-json\/wp\/v2\/media?parent=1810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}